Arrow
Arrow
Slider
Dr Stephen Little

Stephen is a successful serial biotechnology entrepreneur. He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. DxS pioneered the use of molecular diagnostic tests such as KRAS and EGFR mutation analysis to predict the use of novel cancer therapies. In 2009, DxS was acquired by QIAGEN and Stephen became Vice President of Personalised Healthcare, responsible for developing companion diagnostic partnerships with the pharma industry. Prior to his leading role at DxS, Stephen worked for 20 years in various senior positions in the diagnostic divisions of Astra Zeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh.